$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

$tsoi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017729 Filed on May 16, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$26.31K	$23.12K	$84.90K
YoY Change	-32.11%	-72.76%	303.13%
Cost Of Revenue	$10.70K	$8.466K	$15.94K
YoY Change	22.85%	-46.89%	43.86%
Gross Profit	$15.61K	$14.66K	$68.96K
YoY Change	-48.04%	-78.75%	590.98%
Gross Profit Margin	59.33%	63.39%	81.22%
Selling, General & Admin	$349.6K	$391.8K	$291.5K
YoY Change	-31.12%	34.41%	16.04%
% of Gross Profit	2239.61%	2673.13%	422.71%
Research & Development	$208.5K	$52.73K	$304.2K
YoY Change	-65.12%	-82.66%	1443.96%
% of Gross Profit	1336.02%	359.74%	441.07%
Depreciation & Amortization	$76.92K	$2.720K	$6.850K
YoY Change	-23.3%	-60.29%	270.27%
% of Gross Profit	492.79%	18.56%	9.93%
Operating Expenses	$558.1K	$444.5K	$595.7K
YoY Change	-49.51%	-25.37%	119.87%
Operating Profit	-$542.5K	-$429.9K	-$526.7K
YoY Change	-49.55%	-18.38%	101.85%
Interest Expense	$122.3K	$121.8K	-$74.23K
YoY Change	-37.43%	-264.1%	-200.31%
% of Operating Profit
Other Income/Expense, Net	-$19.95K	-$148.0K	-$74.22K
YoY Change	-82.71%	99.42%
Pretax Income	-$562.5K	-$577.9K	-$600.9K
YoY Change	-52.76%	-3.83%	221.49%
Income Tax	$800.00
% Of Pretax Income
Net Earnings	-$562.4K	-$577.9K	-$600.9K
YoY Change	-52.77%	-3.83%	221.49%
Net Earnings / Revenue	-2137.75%	-2499.16%	-707.8%
Basic Earnings Per Share	$0.00	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$251.00
COMMON SHARES
Basic Shares Outstanding	3.022B shares	2.734B shares	2.394B shares
Diluted Shares Outstanding	2.976B shares	2.692B shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.1K	$18.53K	$165.7K
YoY Change	-37.61%	-88.82%	104.28%
Cash & Equivalents	$123.1K	$18.53K	$165.7K
Short-Term Investments
Other Short-Term Assets	$50.83K	$128.5K	$700.1K
YoY Change	-90.61%	-81.64%	288.44%
Inventory	$31.39K	$35.69K	$39.43K
Prepaid Expenses	$16.92K	$31.73K
Receivables	$17.58K	$17.73K	$36.33K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$222.9K	$200.5K	$941.6K
YoY Change	-73.25%	-78.71%	239.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$267.6K	$270.4K	$310.8K
YoY Change	-4.99%	-13.01%	6.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.859M	$2.935M	$97.82K
YoY Change	-16.04%	2900.18%	11.13%
Total Long-Term Assets	$3.265M	$3.349M	$3.840M
YoY Change	-11.97%	-12.77%	638.76%
TOTAL ASSETS
Total Short-Term Assets	$222.9K	$200.5K	$941.6K
Total Long-Term Assets	$3.265M	$3.349M	$3.840M
Total Assets	$3.487M	$3.550M	$4.781M
YoY Change	-23.21%	-25.75%	499.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$362.6K	$398.9K	$372.5K
YoY Change	0.27%	7.11%	24.97%
Accrued Expenses	$569.9K	$544.9K	$514.2K
YoY Change	10.65%	5.97%	-13.38%
Deferred Revenue
YoY Change
Short-Term Debt	$743.5K	$1.056M	$1.074M
YoY Change	-30.12%	-1.68%	1.87%
Long-Term Debt Due	$4.640K	$4.640K	$4.640K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$1.875M	$2.255M	$2.460M
YoY Change	-18.99%	-8.32%	7.68%
LONG-TERM LIABILITIES
Long-Term Debt	$8.080K	$9.300K	$13.89K
YoY Change	-36.78%	-33.05%
Other Long-Term Liabilities	$113.5K	$120.1K	$2.150K
YoY Change	5180.93%	5486.51%	-92.3%
Total Long-Term Liabilities	$121.6K	$129.4K	$16.04K
YoY Change	714.6%	706.8%	-42.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.875M	$2.255M	$2.460M
Total Long-Term Liabilities	$121.6K	$129.4K	$16.04K
Total Liabilities	$1.996M	$2.385M	$2.476M
YoY Change	-14.29%	-3.69%	7.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.81M	-$18.25M
YoY Change	19.17%
Common Stock	$3.134M	$2.749M
YoY Change	22.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.492M	$1.165M	$2.305M
YoY Change
Total Liabilities & Shareholders Equity	$3.487M	$3.550M	$4.781M
YoY Change	-23.21%	-25.75%	499.58%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$562.4K	-$577.9K	-$600.9K
YoY Change	-52.77%	-3.83%	221.49%
Depreciation, Depletion And Amortization	$76.92K	$2.720K	$6.850K
YoY Change	-23.3%	-60.29%	270.27%
Cash From Operating Activities	-$337.1K	-$201.1K	-$214.9K
YoY Change	42.55%	-6.42%	2.28%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$2.750K	$1.950K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.750K	$1.951K	-$200.0K
YoY Change		-100.98%	-12.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	433.4K	$199.6K	486.5K
YoY Change	61.2%	-58.97%	82.39%
NET CHANGE
Cash From Operating Activities	-337.1K	-$201.1K	-214.9K
Cash From Investing Activities	-2.750K	$1.951K	-200.0K
Cash From Financing Activities	433.4K	$199.6K	486.5K
Net Change In Cash	93.55K	$491.00	71.65K
YoY Change	188.91%	-99.31%	-141.89%
FREE CASH FLOW
Cash From Operating Activities	-$337.1K	-$201.1K	-$214.9K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$337.1K	-$201.1K	-$214.9K
YoY Change	42.55%	-6.42%	-954.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001419051
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties		usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022Q1	us-gaap	Proceeds From Sale Of Loans Receivable ProceedsFromSaleOfLoansReceivable		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-54554
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Therapeutic Solutions International, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1226465
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Wild Rose Lane
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Elk City
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	ID
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	83525
CY2023Q1	dei	City Area Code CityAreaCode	(760)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	295-7208
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3021589908	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18531	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18040	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17726	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25398	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	35685	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	42428	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	117506	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	200451	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	309221	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	270358	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	144226	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8612	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2934774	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2023Q1	us-gaap	Assets Assets	3549809	usd
CY2022Q4	us-gaap	Assets Assets	3605531	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	544913	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	531783	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24119	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8612	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	146464	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	175063	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	60536	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	65187	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	227077	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2255355	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2210237	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	9296	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	10507	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	120107	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2384758	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2220744	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2748956631	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2748956631	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2617390830	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2617390830	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2748958	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2617392	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16677708	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16334129	usd
CY2023Q1	TSOI	Shares To Be Issued SharesToBeIssued	9324	usd
CY2022Q4	TSOI	Shares To Be Issued SharesToBeIssued	126324	usd
CY2023Q1	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18249939	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17672058	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1165051	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3549809	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3605531	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23123	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84898	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8466	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15938	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	14657	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	68960	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	119401	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40007	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	110525	usd
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	114285	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	69284	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	87116	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	92587	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	50092	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52727	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	304159	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	444524	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	595659	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-429867	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-526699	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	18134	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-66532	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-44336	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	142306	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	121812	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	149998	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-148014	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-74224	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-577881	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-600923	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-577881	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-600923	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2692056744	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2393701868	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-804982	usd
CY2022Q1	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	29999	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	345000	usd
CY2022Q1	TSOI	Stock Issued During Period Value For License StockIssuedDuringPeriodValueForLicense	3107570	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	228365	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-600923	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2305029	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	19600	usd
CY2023Q1	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	20000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	130086	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	188459	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-577881	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1165051	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1165051	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-577881	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-600923	usd
CY2023Q1	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	19600	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	18134	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-66532	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-44336	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	142306	usd
CY2023Q1	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	60943	usd
CY2022Q1	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	303056	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	106664	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	134031	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	74194	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5693	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2720	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1163	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7672	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19721	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6743	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-383	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37605	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17021	usd
CY2023Q1	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	10630	usd
CY2022Q1	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	6261	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10283	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21586	usd
CY2023Q1	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	8	usd
CY2022Q1	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	-2451	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	44735	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	44243	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10630	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6261	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-201078	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-214865	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Loans Receivable ProceedsFromSaleOfLoansReceivable	1951	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1951	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	8	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2404	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	70750	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	145000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1210	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1077	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	130086	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	345000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	199618	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	486519	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	491	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	71654	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29043	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104259	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29534	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	175913	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	663	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	710	usd
CY2023Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	8500	usd
CY2022Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	11250	usd
CY2023Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	69565	usd
CY2022Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	145000	usd
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	188459	usd
CY2022Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	228365	usd
CY2023Q1	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	20000	usd
CY2022Q1	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	29999	usd
CY2023Q1	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	6479	usd
CY2022Q1	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	6478	usd
CY2023Q1	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue	146244	usd
CY2022Q1	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue	3107570	usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	100000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	146244	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18531	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165690	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	10223	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29534	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175913	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_802_eus-gaap--NatureOfOperations_z5FyWBYDQWhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 1 – <span id="xdx_826_zR4z2Qd0Wys3">Organization and Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized <span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_c20230101__20230331_zNFymGb3v8Kf" title="Entity incorporation date">August 6, 2007</span>, under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Business Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Nutraceutical Division</b> – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. QuadraMune has been shown to increase Natural Killer Cell activity and healthy Cytokine production. Our synergistic blend of ingredients helps the immune system fight off common and complex ailments and promote healthy T Cell activity. Recently the Company was approved to sell certain nutraceuticals on the Amazon Platform.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Cellular Division</b> – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, <span id="xdx_90A_eus-gaap--UnusualOrInfrequentItemNatureOfEventOrTransaction_c20210803__20210804_zXFNHNc4Bj1j" title="Unusual or infrequent item, description">the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.</span> The Company also recently announced the launching of Phase III for IND # 19757 with Biorasi LLC, a global, full-service CRO, who will run the clinical trial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Most recently the Company announced filing of a patent application covering the use stem cell derived exosomes for treatment of aortic aneurysms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>March 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Management does not expect existing cash as of March 31, 2023, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of March 31, 2023, the Company has incurred losses totaling $<span id="xdx_90F_eus-gaap--ProfitLoss_pn5n6_c20230101__20230331_zuCI52a0aTmg" title="Net loss">18.2</span> million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2007-08-06
CY2021Q3	us-gaap	Unusual Or Infrequent Item Nature Of Event Or Transaction UnusualOrInfrequentItemNatureOfEventOrTransaction	the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
CY2023Q1	us-gaap	Profit Loss ProfitLoss	18200000	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	44336	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	227077	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5693	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	258162	usd
CY2023Q1	TSOI	Wholesale Purchase Price And Payments Description WholesalePurchasePriceAndPaymentsDescription	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	227077	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	202144	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	77856	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-97259	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zDOEw7EKuVZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_863_z5jo08luH5U7">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	372997016	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	134887029	shares
CY2023Q1	us-gaap	Depreciation Depreciation	2720	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1163	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	74194	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52727	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	304159	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	856	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1141	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	31732	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62661	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	117506	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2928767	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	144226	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	144226	usd
CY2023Q1	us-gaap	Interest Bearing Domestic Deposit Certificates Of Deposits InterestBearingDomesticDepositCertificatesOfDeposits	10000	usd
CY2023Q1	us-gaap	Weighted Average Rate Domestic Deposit Certificates Of Deposit WeightedAverageRateDomesticDepositCertificatesOfDeposit	0.006	pure
CY2023Q1	us-gaap	Restricted Cash Current Nature Of Restriction Description RestrictedCashCurrentNatureOfRestrictionDescription	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.
CY2023Q1	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	84918	usd
CY2022Q4	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	148550	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301359	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301359	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31001	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28281	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	270358	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2720	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1163	usd
CY2023Q1	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	1884	usd
CY2022Q4	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	7537	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2023Q1	TSOI	Licenses Noncurrent LicensesNoncurrent	2928767	usd
CY2022Q4	TSOI	Licenses Noncurrent LicensesNoncurrent	3002960	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2934774	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	332355	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3002960	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	74194	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5693	usd
CY2023Q1	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	4505000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4500000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2748956631	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2748956631	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Area Of Land AreaOfLand	1700	sqft
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P60M
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2028-04-30
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	6261	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	6261	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure

Files In Submission

Name	View Source	Status
0001493152-23-017729-index-headers.html	Edgar Link	pending
0001493152-23-017729-index.html	Edgar Link	pending
0001493152-23-017729.txt	Edgar Link	pending
0001493152-23-017729-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsoi-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
tsoi-20230331_cal.xml	Edgar Link	unprocessable
tsoi-20230331_lab.xml	Edgar Link	unprocessable
tsoi-20230331_pre.xml	Edgar Link	unprocessable
tsoi-20230331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2023 Q2 Form 10-Q Financial Statement

#000149315223017729 Filed on May 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2023 Q2 Form 10-Q Financial Statement

#000149315223017729 Filed on May 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi